Pacira BioSciences Posts Strong Q2 Growth, Boosts 2025 Revenue Guidance

Pacira BioSciences reported a 6% growth in EXPAREL volume, its highest in eight quarters, and entered a collaboration with Johnson & Johnson MedTech to enhance ZILRETTA's market presence. The company updated its revenue guidance for 2025, projecting between $730 million and $750 million. Analysts forecast an average price target of $41.83, suggesting an 85.60% upside potential from the current trading price.

Pacira BioSciences Inc. (Nasdaq: PCRX) has reported a robust second quarter, with notable growth in its EXPAREL product and the establishment of a strategic collaboration with Johnson & Johnson MedTech. The company also updated its full-year revenue guidance for 2025, projecting between $730 million and $750 million.

In the second quarter, EXPAREL sales reached $142.9 million, marking a 6% increase year-over-year, the highest volume growth in eight quarters [1]. This growth was driven by a 6% volume increase, despite a shift in vial mix and discounting that partially offset the growth. ZILRETTA sales grew to $31.3 million, up from $30.7 million in the prior year, while iovera° sales decreased slightly to $5.6 million from $5.7 million [1].

Pacira BioSciences also reported a non-GAAP gross margin of 82%, an improvement from 76% in the previous year, and adjusted EBITDA of $54.3 million for the second quarter [1]. The company's non-GAAP R&D expense increased to $24.7 million from $18.4 million, while non-GAAP SG&A expenses rose to $77.2 million from $59 million, reflecting investments in commercial and market access initiatives [1].

The company's strategic collaboration with Johnson & Johnson MedTech is expected to enhance the market presence of ZILRETTA, potentially doubling its reach. Pacira BioSciences is also on track to reach 60 million covered commercial lives by the end of 2025, driven by its focus on expanding market access for EXPAREL [1].

Pacira BioSciences updated its full-year 2025 revenue guidance to $730 million to $750 million, a narrowing of the previous range, and increased its non-GAAP gross margin guidance to 78% to 80% for 2025 [1]. The company also repurchased 2.0 million shares at an average price of $25.59 per share, totaling $50.0 million, and had $250.0 million remaining on its current share repurchase authorization [2].

Analysts forecast an average price target of $41.83 for Pacira BioSciences, suggesting an 85.60% upside potential from the current trading price [2].

References:
[1] https://finance.yahoo.com/news/pacira-biosciences-inc-pcrx-q2-072746663.html
[2] https://www.stocktitan.net/news/PCRX/pacira-bio-sciences-reports-second-quarter-2025-financial-40vq37cmvwv7.html